| 04/09/2024 15:00 |
Notice concerning Revisions to Financial Forecasts for the Fiscal Year Ended March 31, 2024 |
| 03/29/2024 10:05 |
Corporate Governance Report |
| 03/19/2024 13:00 |
Notice concerning Positive Results of Phase III Study of Bivalent Version of Kostaive, Self-Amplifying mRNA Vaccine Against COVID-19 |
| 02/08/2024 14:00 |
(Updated)Notice concerning Amendment to Earnings Report of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ended Mar. 31, 2023 |
| 02/08/2024 14:00 |
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024 [Based on Japanese GAAP] |
| 01/10/2024 15:00 |
Notice concerning Capital Increase of Sub-Subsidiary (to be a Designated Subsidiary) to Invest in Production Capacity of Tablet Baby Formula Products |
| 12/12/2023 15:00 |
First-Time Selection to the Dow Jones Sustainability World Index |
| 12/06/2023 16:00 |
Notice concerning New Plant Construction in East Hokkaido and the Reorganization of Our Production Structure |
| 12/06/2023 10:00 |
Notice concerning the Initiation of Pediatric Phase III Clinical Trial of KD-414, a COVID-19 Vaccine Effective against Mutant Strains |
| 11/28/2023 15:00 |
KostaiveTM, Self-Amplifying mRNA Vaccine against COVID-19, Approved for Manufacturing and Marketing from MHLW in Japan |
| 11/09/2023 14:00 |
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2024 [Based on Japanese GAAP] |
| 11/07/2023 16:00 |
Notice Concerning Revisions to Financial Forecasts for the Fiscal Year Ending March 31, 2024 |
| 10/16/2023 15:00 |
Notice concerning Submission of Clinical Trial Notification for Pediatric Phase III of KD-414, a COVID-19 Vaccine Effective against Mutant Strains |
| 09/25/2023 15:00 |
Notice concerning Completion of Payment in Full and Partial Forfeiture of Rights for Disposal of Treasury Stock under Restricted Stock Incentive Plan |
| 08/08/2023 14:00 |
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2024 [Based on Japanese GAAP] |
| 08/04/2023 15:00 |
Notice concerning Completion of Payment in Full for Disposal of Treasury Stock for Restricted Stock Compensation for Directors |
| 07/07/2023 16:00 |
Notice concerning the Disposal of Treasury Stock under Restricted Stock Incentive Plan for Employees in Managerial Positions |
| 07/07/2023 16:00 |
Notice concerning the Disposal of Treasury Stock for Restricted Stock Compensation for Directors |
| 06/30/2023 17:00 |
Additional Application for Booster Dose of ARCT-154, Self-Amplifying mRNA Vaccine against COVID-19, Submitted in Japan |
| 06/29/2023 15:00 |
Corporate Governance Report |
| 05/31/2023 08:00 |
Notice of the 14th Ordinary General Meeting of Shareholders |
| 05/11/2023 14:00 |
Notice concerning Surplus Dividends |
| 05/11/2023 14:00 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 [Based on Japanese GAAP] |
| 04/28/2023 17:00 |
Submitted New Drug Application to Manufacture and Market ARCT-154, Next Generation mRNA Vaccine against COVID-19, in Japan |
